Are we ready to move away from nature? The rapamycin story

作者: Monica Mita , Alain Mita , None

DOI: 10.1007/S11523-011-0183-8

关键词:

摘要: We have seen it all in cancer treatment. work with tree extracts, marine sponges, viruses, soil and many other things. Nature has giving us the tools to treat this threatening disease will continue do so if we an open mind are willing learn; gained extensive knowledge from rapamycin story. It started a far-far away Island (Easter Island) bacteria identification of microcyclic antibiotic antifungal properties. Twenty years later. know (or think know) target (TOR), TOR complexes, upstream downstream effectors, elements that activate or inhibit pathway, start seeing promising effects targeting mammalian (mTOR) not only but also conditions such as inflammation aging. mother compound approved for graft rejection, rapamycin-coated arterial stents. three analogs improved pharmacological properties usethemtotreatvariousmalignancies[1–4]. patients benefiting treatment rapalogs doing remarkably well prolonged time almost no change quality life. very familiar toxicity profile believe they safe compatible use [5].

参考文章(8)
Scott A. Soefje, Anand Karnad, Andrew J. Brenner, Common toxicities of mammalian target of rapamycin inhibitors. Targeted Oncology. ,vol. 6, pp. 125- 129 ,(2011) , 10.1007/S11523-011-0174-9
Sumanta Kumar Pal, Robert A. Figlin, Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma. Targeted Oncology. ,vol. 6, pp. 5- 16 ,(2011) , 10.1007/S11523-011-0172-Y
Yesid Alvarado, Monica M Mita, Sushma Vemulapalli, Devalingam Mahalingam, Alain C Mita, None, Clinical activity of mammalian target of rapamycin inhibitors in solid tumors Targeted Oncology. ,vol. 6, pp. 69- 94 ,(2011) , 10.1007/S11523-011-0178-5
Kevin R. Kelly, Julie H. Rowe, Swaminathan Padmanabhan, Steffan T. Nawrocki, Jennifer S. Carew, Mammalian target of rapamycin as a target in hematological malignancies Targeted Oncology. ,vol. 6, pp. 53- 61 ,(2011) , 10.1007/S11523-011-0175-8
Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova, Eric Raymond, Sandrine Faivre, Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors. Targeted Oncology. ,vol. 6, pp. 119- 124 ,(2011) , 10.1007/S11523-011-0177-6
Shin Ogita, Patricia LoRusso, Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Targeted Oncology. ,vol. 6, pp. 103- 117 ,(2011) , 10.1007/S11523-011-0176-7
Zelton Dave Sharp, Arlan Richardson, Aging and cancer: can mTOR inhibitors kill two birds with one drug? Targeted Oncology. ,vol. 6, pp. 41- 51 ,(2011) , 10.1007/S11523-011-0168-7